Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JUN | P05412 | 6/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 6/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 6/20 | 0.36 |
| ▸ | RELA | Q04206 | 6/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30587587 | 1.00 | JUN (0.36) | JUNNFKB1NFKB2RELA | |
| SCHEMBL22888305 | 1.00 | JUN (0.36) | JUNNFKB1NFKB2RELA | |
| SCHEMBL18372843 | 0.79 | JUN (0.35) | JUNNFKB1NFKB2RELA | |
| SCHEMBL30587500 | 0.75 | MAP4K1 (0.36) | JUNNFKB1NFKB2RELA | |
| SCHEMBL18366598 | 0.75 | MAP4K1 (0.36) | JUNNFKB1NFKB2RELA | |
| SCHEMBL18367348 | 0.73 | CCNC (0.33) | — | |
| SCHEMBL18366594 | 0.72 | MAP4K1 (0.31) | — | |
| SCHEMBL30092698 | 0.72 | MAP4K1 (0.31) | — | |
| SCHEMBL18367165 | 0.70 | DGAT1 (0.31) | JUNNFKB1NFKB2RELA | |
| SCHEMBL18366790 | 0.70 | DGAT1 (0.31) | JUNNFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10988459-B2 | Bicyclic lactams and methods of use thereof | GENENTECH, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| EP-3760625-A1 | BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES | F. Hoffmann-La Roche AG (CH) | 2021-01-06 | — | — | EP | disclosed |
| WO-2017004500-A9 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| US-20170008877-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-12 | — | — | US | disclosed |
| US-20170008877-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-12 | — | — | US | disclosed |
| WO-2017004500-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10988459-B2 | Bicyclic lactams and methods of use thereof | LSS, LPXN, CYP1B1 | JUN 4174/4885NFKB1 1394/4885NFKB2 2348/4885 |
| US-20170008877-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | LSS, LPXN, CYP1B1 | JUN 4174/4885NFKB1 1394/4885NFKB2 2348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.